Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
morte-mescaline
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Morte-mescaline appears to be a formulation or derivative of mescaline (3,4,5-trimethoxyphenethylamine) being investigated for medical use. It is being studied in comparison with mescaline sodium enteric-coated tablets for the treatment of adult lupus nephritis. Unlike traditional mescaline, which is primarily known as a hallucinogenic substance found in certain cacti and classified as a Schedule I controlled substance, morte-mescaline seems to be developed for potential therapeutic applications.
- Brand names
- CellCept
- Other names
- MMFmycophenolate mofetil
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on morte-mescaline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on morte-mescaline.